An Overview of Clinical Trials on the Duration of Dual Antiplatelet Therapy and the Scope of Novel Oral Anticoagulants Following Percutaneous Coronary Intervention

Abstract

ABSTRACT After percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) is an important therapy for preventing thrombotic events. Numerous clinical trials have been conducted to determine the ideal length of therapy in relation to the duration of DAPT. Similar to this, various clinical trials have investigated the use of novel oral anticoagulant (NOAC) medication in conjunction with DAPT following PCI. In this review, we sum up the findings from various significant clinical studies that have influenced the duration of DAPT and the scope of NOAC therapy following PCI.